Louise Pierneef

Field-deployable immunodiagnostics for poverty-associated infectious diseases

Leprosy and tuberculosis (TB) remain significant public health challenges in low- and middle-income countries, where limited access to rapid and reliable diagnostics leads to delayed detection and continuous transmission. In leprosy, diagnosis is largely dependent on clinical recognition, which means infections are often established late, and asymptomatic transmission can remain unnoticed. TB diagnostics, on the other hand, are heavily dependent on sputum-based laboratory tests, which are not always applicable in vulnerable populations and depend on a limited and sometimes fragile diagnostic infrastructure. Together, these limitations underscore the need for fast, user-friendly diagnostic tools suitable for use in the field that enable both early detection of infection and monitoring of transmission at the population level.

This dissertation investigates the development, validation, and implementation of field-deployable immunodiagnostic tools based on the UCP-LFA platform for the detection and monitoring of infectious diseases associated with poverty, with a primary focus on leprosy and additional applications for TB and COVID-19. By combining technological innovation in diagnostic tests with large-scale field studies, this research aims to contribute to more effective strategies for disease control and surveillance in environments with limited resources and infrastructure.

The elimination of leprosy is focused on interrupting the transmission of Mycobacterium leprae (M. leprae), which is not limited to patients' households. Because the interruption of transmission has not yet been achieved in many countries, there is a need for a test that can identify infected asymptomatic individuals who can sustain transmission. To monitor the elimination of leprosy, it is essential to identify suitable indicators that reflect transmission within a population. Antibodies against M. leprae antigens indicate infection but cannot distinguish between a recent or previous infection. In this context, Chapter 2 describes a systematic review of the available literature on serological tests for anti-M. leprae antibodies in children without clinical leprosy living in endemic areas. Given that antibody responses in young children by definition indicate recent infection, this chapter investigated whether anti-PGL-I seroprevalence could be used as a measure of the current transmission of M. leprae. A literature search was conducted in PubMed, Infolep, Web of Science, and the Virtual Health Library. Thirty articles from ten countries met the inclusion criteria. All studies measured antibodies against phenolic glycolipid-I (PGL-I) or synthetic variants thereof, both quantitatively (ELISA or UCP-LFA) and qualitatively (ML-flow or NDO-LID rapid tests). The median seroprevalence in children in endemic areas was 14.9% and remained stable over time when disease incidence did not change. Although quantitative anti-PGL-I serology among young children seemed promising as a proxy for transmission, comparisons between areas were limited by differences in the tests and cut-off values used.

In Chapter 3, the final version of a quantitative rapid test for the detection of M. leprae infection is evaluated, the PGL-I QURapid. This test, based on UCP-LFA technology, measures anti-PGL-I IgM antibodies in fingerstick blood and serum. This chapter examines the diagnostic performance, reproducibility, and applicability of the test in field conditions. It is demonstrated that the test can identify multibacillary leprosy patients with high sensitivity and specificity in both fingerstick blood and serum, while results are available within a few minutes. The use of a humanized recombinant anti-PGL-I IgM control is also described, which allows for the monitoring of test performance and the establishment of standardized cut-off values. The results show that the PGL-I QURapid meets the criteria set by the WHO for point-of-care diagnostics and is suitable for implementation within public health programs in endemic areas.

In Chapter 4, a field study conducted in the state of Bihar in India is described. In this study, the quantitative UCP-LFA test was used to determine the seroprevalence of anti-PGL-I IgM antibodies in 1,857 children aged three to eleven years, from twelve endemic villages. This chapter investigates to what extent seropositivity in young children can serve as an indicator for recent M. leprae transmission in endemic areas. The results show that 11.58% of the children were seropositive for anti-PGL-I IgM, a level comparable to previous studies in other endemic regions without prophylactic interventions. Furthermore, the UCP-LFA is described as an accessible and practically applicable instrument that integrates well into large-scale serosurveys and was well accepted by both local healthcare staff and the involved communities. The findings support the potential of anti-PGL-I serology in children as a tool to monitor recent transmission of M. leprae in the context of leprosy elimination programs.

Chapter 5 describes a second sero-epidemiological study in rural and urban areas in Indonesia. In this study, anti-PGL-I IgM seroprevalence was determined in 637 school-going children (6–15 years) using the field-deployable quantitative UCP-LFA test (PGL-I QURapid), also considering socioeconomic factors and the presence of worm infections. The results show that the total seroprevalence was 12.2%, with clear differences between regions: in rural areas, significantly higher percentages were found (up to 31.0% in Southwest Sumba) than in urban areas (3.1–3.8%). Additionally, seroprevalence was significantly higher among children from low socioeconomic schools (13.7%) compared to high SES schools (4.1%). A strong association was also found between worm infections and increased anti-PGL-I IgM levels; children with a worm infection were more likely to be seropositive than children without infection. These findings indicate increased M. leprae transmission in rural, socioeconomically vulnerable, and worm-infected populations. The chapter emphasizes the importance of integrated infectious disease control, including both leprosy and worm infections. Furthermore, it is confirmed that the PGL-I QURapid is an effective instrument for serological monitoring and identifying hotspots with increased transmission, which can support targeted interventions in endemic areas.

In Chapter 6, the implementation of large-scale serological monitoring within the Post-ExpOsure Prophylaxis for LEprosy (PEOPLE) study in the Comoros and Madagascar (2019–2023) is described. In this study, different methods of administering post-exposure prophylaxis with rifampicin to contacts of leprosy patients were evaluated, combined with active case finding of new cases. Additionally, in 16 of the 64 participating villages, anti-PGL-I IgM seroprevalence was measured for three consecutive years among newly diagnosed leprosy patients and more than 17,000 household and neighborhood contacts. Fingerstick blood was analyzed on-site by local personnel using the field-deployable quantitative UCP-LFA test. The results show that 92.5% of multibacillary patients with a bacterial index of ≥1 were seropositive, confirming the high sensitivity of the test in field conditions. Prior to interventions, seroprevalence among contacts varied between 21.9% and 27.4% across different locations. After two years of active case finding and prophylaxis administration, seroprevalence in all study areas had significantly decreased to 11.6%–22.8%. Furthermore, a significant decrease in anti-PGL-I IgM levels was observed at the individual level in initially seropositive individuals. This decline was seen regardless of whether or not prophylaxis was received. The findings suggest that the combination of active case finding and prophylaxis leads to a decrease in M. leprae infection levels in the population. This chapter thus shows that the anti-PGL-I UCP-LFA is suitable for large-scale serological surveillance and monitoring the impact of leprosy control interventions at the population level.

In Chapter 7, the scope of the dissertation is expanded by examining the application of host biomarker-based UCP-LFAs for another mycobacterial disease: TB. In this chapter, the diagnostic performance of these assays for distinguishing active and latent TB is investigated, as well as COVID-19 patients and healthy controls, and the usability of these tests for triage purposes is discussed. The results show that the studied biomarkers offer a high degree of diagnostic accuracy, including distinguishing between latent infection and active TB (AUC 0.94), and differentiating between healthy individuals and COVID-19 patients (AUC 0.99). Additionally, these markers appear useful for monitoring treatment in both TB and COVID-19. This chapter demonstrates that non-sputum-based quantitative LFAs can form a promising alternative as a supplementary diagnostic and monitoring tool for respiratory infectious diseases and underscores the broader applicability of the UCP-LFA platform.

In summary, this dissertation shows that the UCP-LFA platform forms a versatile and scalable diagnostic system for the detection and monitoring of infectious diseases in diverse epidemiological contexts. For leprosy, quantitative anti-PGL-I IgM serology appears to be a valuable indicator of infection and transmission, with applications ranging from individual diagnostics to large-scale serosurveillance and evaluation of public health interventions. The results from field studies in India, Indonesia, the Comoros, and Madagascar demonstrate that this approach is not only suitable for identifying infected individuals but also for detecting hidden transmission hotspots and tracking changes in infection levels over time. Additionally, the findings highlight the importance of integrated strategies where diagnostics, treatment, and prevention are deployed together and tailored to local epidemiological and socioeconomic circumstances. The results for TB and COVID-19 illustrate the broad applicability of the UCP-LFA platform for various infectious diseases. Host biomarker-based UCP-LFAs offer potential as rapid, non-invasive tools suitable for the field for both triage and monitoring of respiratory infectious diseases, especially in settings where access to laboratory diagnostics is limited. Finally, this dissertation underscores that the greatest impact lies not only in developing perfect diagnostic tests but in the smart deployment of available tools within realistic public health strategies. Even when diagnostic methods do not fully answer all clinical or epidemiological questions, they can still provide crucial information to detect transmission, guide interventions, and bring elimination goals closer.

Lees verder
Publicatiedatum 10 september 2026
Universiteit Universiteit Leiden
Auteur Louise Pierneef

Bekijk ook deze projecten

Esther Barsom

Esther Barsom

Universiteit Leiden Lees meer
Eline Schaft

Eline Schaft

Universiteit Leiden Lees meer
Kirsten de Oude

Kirsten de Oude

Universiteit Leiden Lees meer